Kinnate Biopharma Future Growth
Future criteria checks 0/6
Kinnate Biopharma is forecast to grow earnings and revenue by 14.6% and 69.1% per annum respectively while EPS is expected to grow by 33.6% per annum.
Key information
14.6%
Earnings growth rate
33.6%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 69.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 03 Apr 2024 |
Recent future growth updates
Recent updates
Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?
Jun 11
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely
Jan 04FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor
Sep 21Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans
Sep 15Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03
Aug 11We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely
May 15Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth
Jan 24We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth
Oct 09Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation
Jun 22We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate
Mar 03Kinnate Biopharma earns bulls as IPO quiet period ends
Dec 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -69 | -36 | -23 | 2 |
| 12/31/2025 | N/A | -53 | -37 | -37 | 3 |
| 12/31/2024 | N/A | -59 | -54 | -54 | 4 |
| 12/31/2023 | N/A | -113 | -100 | -100 | N/A |
| 9/30/2023 | N/A | -127 | -107 | -106 | N/A |
| 6/30/2023 | N/A | -127 | -102 | -102 | N/A |
| 3/31/2023 | N/A | -122 | -96 | -96 | N/A |
| 12/31/2022 | N/A | -116 | -92 | -89 | N/A |
| 9/30/2022 | N/A | -111 | -91 | -88 | N/A |
| 6/30/2022 | N/A | -105 | -88 | -85 | N/A |
| 3/31/2022 | N/A | -99 | -81 | -79 | N/A |
| 12/31/2021 | N/A | -90 | -72 | -71 | N/A |
| 9/30/2021 | N/A | -77 | -62 | -62 | N/A |
| 6/30/2021 | N/A | -63 | -53 | -53 | N/A |
| 3/31/2021 | N/A | -49 | -41 | -41 | N/A |
| 12/31/2020 | N/A | -36 | -30 | -30 | N/A |
| 9/30/2020 | N/A | -26 | -20 | -20 | N/A |
| 12/31/2019 | N/A | -10 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KNTE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KNTE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KNTE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KNTE is forecast to have no revenue next year.
High Growth Revenue: KNTE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KNTE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/03 18:15 |
| End of Day Share Price | 2024/04/03 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kinnate Biopharma Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Choi | Goldman Sachs |
| Roger Song | Jefferies LLC |
| Andrew Berens | Leerink Partners LLC |